Eddie Hickman
Stock Analyst at Guggenheim
(4.35)
# 360
Out of 5,050 analysts
18
Total ratings
64.71%
Success rate
17.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eddie Hickman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TARS Tarsus Pharmaceuticals | Maintains: Buy | $84 → $87 | $68.25 | +27.47% | 9 | Nov 5, 2025 | |
| OTLK Outlook Therapeutics | Downgrades: Neutral | n/a | $1.19 | - | 4 | Aug 29, 2025 | |
| PMN ProMIS Neurosciences | Reiterates: Buy | $6 | $0.38 | +1,483.11% | 2 | Apr 1, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $20 → $22 | $8.81 | +149.72% | 1 | Mar 13, 2025 | |
| GHRS GH Research | Initiates: Buy | $32 | $13.50 | +137.04% | 1 | Mar 13, 2025 | |
| CYBN Cybin | Initiates: Buy | $35 | $5.98 | +485.28% | 1 | Mar 13, 2025 |
Tarsus Pharmaceuticals
Nov 5, 2025
Maintains: Buy
Price Target: $84 → $87
Current: $68.25
Upside: +27.47%
Outlook Therapeutics
Aug 29, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.19
Upside: -
ProMIS Neurosciences
Apr 1, 2025
Reiterates: Buy
Price Target: $6
Current: $0.38
Upside: +1,483.11%
Zevra Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $20 → $22
Current: $8.81
Upside: +149.72%
GH Research
Mar 13, 2025
Initiates: Buy
Price Target: $32
Current: $13.50
Upside: +137.04%
Cybin
Mar 13, 2025
Initiates: Buy
Price Target: $35
Current: $5.98
Upside: +485.28%